Explain It in 30 Seconds
Empagliflozin is an SGLT2 inhibitor. Its clinical and commercial role is distinct from insulin and from GLP-1-based products, even though these medicines can appear within the broader cardiometabolic market. [S29]
The product also illustrates an important accounting boundary. Jardiance's overall sales, the sales of its related combination family and the revenue Lilly recognizes from the collaboration are different measures. Understanding the business requires knowing which measure is being discussed.
A Product with Several Clinical Pathways
Current US product information includes glucose-control use in a defined type 2 diabetes population, cardiovascular-risk reduction in a specified population, and separate adult heart-failure and chronic-kidney-disease roles. The heart-failure and kidney-disease indications are not simply a restatement of glucose control. [S29]
Those uses connect different specialists and care objectives. A diabetes-centered pathway can differ from a heart-failure or kidney-care pathway, even where some patients have overlapping conditions.
For the business, evidence across several settings can broaden relevance. It does not make the product a universal treatment for every person with any cardiovascular or renal condition. The actual populations and limitations remain material.
How the Mechanism Differs
SGLT2 inhibition affects kidney handling of glucose, including increased urinary glucose excretion. That is a different mechanism from supplying insulin or activating GLP-1 pathways. [S29]
The product's broader outcomes still rest on clinical evidence rather than a simple assumption that all benefit follows directly from lowering blood glucose. Separate studies and approvals establish the supported uses.
This distinction helps explain why a cardiometabolic portfolio can contain several scientifically different products. A common disease area does not make the therapies duplicates or erase the need for individualized professional decisions.
What the Alliance Actually Does
Lilly and Boehringer Ingelheim have an agreement to develop and commercialize a portfolio of compounds. Lilly's filing identifies Boehringer's Jardiance family as a significant part of that collaboration and describes Lilly receiving a share of net sales under the agreement. [S1]
The allocation of responsibilities can vary by market and change through amendments. A partnership is therefore a set of defined activities and rights, not one permanent universal division of every task.
The Boehringer relationship is part of the product's commercial identity. Inclusion in Lilly's portfolio does not establish sole Lilly origin, worldwide ownership or entitlement to all sales generated by the alliance. [S1]
Brand, Family and Reporting Line Are Different Units
Jardiance is the empagliflozin brand, while Lilly's reporting descriptions also refer to a product family including related combination medicines. A financial line using the family name can therefore cover more than the single branded tablet. [S1]
Combination products have their own ingredients and information. They are not merely additional package sizes of Jardiance, and the inclusion of one ingredient does not make every combination's label identical.
The distinction is particularly important when comparing sales figures. One company may discuss worldwide brand sales, while another reports its recognized alliance revenue for a wider family. Those figures cannot be treated as directly interchangeable market-share measures.
How Lilly Recognizes the Economics
Lilly's FY2025 filing reports approximately $3.432 billion of Jardiance-related revenue and explains its collaboration-and-other-revenue treatment. That is Lilly's reported amount under the arrangement, not the product's entire global market sales. [S1]
The reporting can also contain items beyond recurring demand. Amendments and sales-based milestones have affected Jardiance revenue. The Q2 2026 release specifically identifies a sales-based milestone associated with the collaboration. [S3]
An increase in the reported line can therefore reflect product performance and contractual events. The business analysis needs both, rather than assuming every additional dollar represents another identical prescription sold directly by Lilly.
Patients, Prescribers and Payers
Patients receive the medicine within a care plan. Clinicians evaluate the actual condition and product suitability, while pharmacies and access processes support supply. Payers influence the terms under which treatment is funded.
Those roles can differ across the product's uses. The existence of a common medicine does not mean every patient follows the same diagnostic, benefit or monitoring pathway.
The manufacturer and alliance can support access, evidence and supply without taking over the independent clinical decision. Actual use depends on the healthcare system as well as the commercial agreement between the companies.
Access and Realized Value
Published price, patient payment and the alliance's net sales are distinct. Rebates, discounts and distribution arrangements influence the amounts retained, and Lilly receives the economics specified by its own participation. [S1][S2]
Broader coverage can change both volume and effective price. A product can become more widely used without every participant receiving the same revenue per prescription as before.
The payer's comparison also concerns the evidence in the relevant population and available alternatives. A product's several indications create potential value, but approval alone does not guarantee unrestricted coverage or identical access in every market.
Safety and Product Limits
The current information includes important risks such as ketoacidosis, volume depletion and serious genitourinary infections, alongside other limitations. Those risks make clinical assessment and appropriate use integral to the product rather than secondary to its commercial reach. [S29]
An oral format does not make the medicine a general consumer product. Its clinical role, interactions and individual suitability remain matters for healthcare professionals.
The business consequence is that the reachable population is shaped by more than prevalence of the conditions. Product limitations, access and care capacity all affect actual use.
Why It Matters to Lilly
Jardiance gives Lilly participation in a meaningful franchise through collaboration rather than a solely owned development and sales model. It broadens the company's cardiometabolic economics while preserving a distinct partner relationship.
It also demonstrates why financial definitions are essential to a company explanation. A reported revenue stream can be commercially important without representing every product unit sold or every dollar paid globally.
The durable opportunity depends on the product's continuing clinical role and the contractual terms through which each company participates. Both the medicine and the alliance have to be understood to explain the business.
Common Questions
Is Jardiance an insulin or GLP-1 product?
No. Empagliflozin is an SGLT2 inhibitor with a different mechanism. [S29]
Are Lilly's reported figures all worldwide Jardiance sales?
Does everyone using it necessarily have diabetes?
No. The current adult heart-failure and kidney-disease indications are separate from the glucose-control use. [S29]
Evidence
Connected Entities
Mounjaro and Lilly Insulins explain different therapeutic and commercial roles. How Lilly Renews Its Medicine Portfolio explains alliance economics alongside licensing and acquisitions.